Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter/X @MolecularPrtnrs.
Company profile
Ticker
MOLN, MLLCF
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Latest filings (excl ownership)
6-K
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
14 Jun 24
6-K
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
11 Jun 24
6-K
Current report (foreign)
3 Jun 24
6-K/A
Current report (foreign) (amended)
17 May 24
6-K
Current report (foreign)
16 May 24
6-K
Molecular Partners Publishes Invitation to Annual General Meeting 2024
26 Mar 24
20-F
2023 FY
Annual report (foreign)
14 Mar 24
6-K
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
8 Jan 24
6-K
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
5 Jan 24
6-K
Current report (foreign)
11 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q3 2023
14.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 8 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 3.91 bn |
Total shares | 5.47 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 4.51 mm | $0.00 |
BVF | 443.22 k | $1.77 bn |
Suvretta Capital Management | 400.00 k | $1.66 bn |
Tang Capital Management | 100.00 k | $414.00 mm |
Susquehanna International | 16.58 k | $66.13 mm |
MS Morgan Stanley | 367.00 | $1.52 mm |
Rhumbline Advisers | 269.00 | $1.07 mm |
Qube Research & Technologies | 16.00 | $64.00 k |
Proequities | 0.00 | $0.00 |
News
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
20 Jun 24
12 Health Care Stocks Moving In Thursday's Intraday Session
20 Jun 24
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
20 Jun 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
20 Jun 24
Market-Moving News for June 14th
14 Jun 24
Press releases
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
17 Jun 24
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
14 Jun 24
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
11 Jun 24
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
1 Jun 24
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
16 May 24